Escape From Synthetic T Cell Activator Tebentafusp by Genomic HLA Loss: A Case Report - PubMed
3 hours ago
- #Uveal melanoma
- #Tebentafusp resistance
- #HLA loss
- Tebentafusp is a standard treatment for HLA-A*02:01-positive metastatic uveal melanoma.
- A patient developed resistance to tebentafusp after 30 months of treatment.
- Resistance was due to genomic loss of the HLA-haplotype containing HLA-A*02:01.
- This loss prevented presentation of tebentafusp's target antigen.
- Understanding resistance mechanisms is crucial for monitoring and early intervention strategies.